Cannabis M&A

Tilray’s $44 million BrewDog acquisition signals a major shift as a Canadian cannabis company expands into craft beer, positioning itself for future THC beverage markets.

A stalled multi-million dollar expansion reveals the real cannabis business growth challenges behind rapid scale in cultivation and real estate.

Cannabis sales are hitting records in both the U.S. and Canada. With Schedule III reform advancing, growth is fueling investment and M&A.

Nature’s Miracle plans a $150 million greenhouse in California City. Here is how its scale compares to Glass House and what it means for the California flower market.

Seller financing is common in cannabis deals, not by choice but by necessity. This analysis explores where these deals quietly go wrong after closing.

Cannabis vape sales have overtaken flower in California for the first time. The shift highlights durable consumer demand and growing M&A focus on manufacturing.

Schedule III is already influencing how cannabis companies think about expansion, research, and consolidation. Early strategic positioning by public operators may have lasting implications for cannabis M&A.

Cannabis sales are breaking records nationwide. New York, Missouri, Massachusetts, and emerging markets are driving demand and reshaping the industry.

Cannabis M&A under Schedule III is accelerating as strategic buyers acquire cannabis brands with durable equity, IP, and consumer trust.

How Mid-Market Acquisitions Point to Broader Consolidation Ahead For much of the past several years, cannabis mergers and acquisitions have felt frozen in place. Capital markets were cautious, valuations faltered, and many buyers sat on the sidelines. But that appears to be changing. A series of recent deals — from strategic infrastructure buys to brand consolidations — suggests that cannabis M&A activity is beginning to heat up. While none of these deals are traditional “blo